poisar

Stocks · News reference

Reported Earlier, Anteris Technologies Glb Q2 EPS $(0.30) Misses $(0.21) Estimate, Sales $1.009M Miss $1.500M Estimate

Benzinga Newsdesk

Anteris Technologies Glb (NASDAQ:AVR) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.21) by 42.86 percent. This is a 48.28 percent increase over losses of $(0.58) per

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

AVR
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGAR

    8-K filing — Anteris Technologies Global Corp. (AVR)

    Filed: 2026-09-08 AccNo: 0001140361-26-035840 Size: 284 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits

    AVR
  2. Na

    Anteris to Present at September Healthcare Investor Conferences

    Anteris Technologies Global Corp. announced that Vice Chairman and CEO Wayne Paterson will present at three major healthcare conferences in September 2026: Cantor Global Healthcare Conference (Sept 9), Wells Fargo 21st Annual Healthcare Conference (Sept 10), and Morgan Stanley 24th Annual Global Healthcare Conference (Sept 14). The company is showcasing its DurAVR® Transcatheter Heart Valve, a biomimetic device designed to treat aortic stenosis.

    AVR